Stockscreener 앱 받기
61.74
0.65%
0.40
시간 외 거래:
61.95
0.21
+0.34%
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - markets.businessinsider.com
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - MSN
Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus
Canaccord maintains Buy on Rhythm Pharma following Ph3 data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid P - GuruFocus
Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus
Rhythm Pharmaceuticals Stock (RYTM) Erases YTD Losses This Week - AskTraders.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target By Investing.com - Investing.com Canada
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - MSN
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade - MSN
Rhythm’s setmelanotide cuts BMI by 20% - The Pharma Letter
Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating - MarketScreener
Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target - Investing.com
Rhythm Pharmaceuticals shares rise on raised target to $80 By Investing.com - Investing.com UK
Canaccord raises Rhythm Pharma stock target to $92, maintains buy By Investing.com - Investing.com Canada
Positive Phase 3 Results and Market Potential Boost Rhythm Pharmaceuticals’ Price Target - TipRanks
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) Surges as Obesity Drug Achieves Ke - GuruFocus
Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News
Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success - insights.citeline.com
Rhythm Pharmaceuticals’ Bold Moves: What’s Next? - timothysykes.com
Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley - TipRanks
Rhythm posts late-stage trial win for lead asset against rare form of obesity - MSN
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish - MSN
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 By Investing.com - Investing.com Canada
Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha
Rhythm Pharmaceuticals (RYTM) Achieves Success in Phase 3 Obesit - GuruFocus
Rhythm Pharmaceuticals Plans Regulatory Filings After Positive I - GuruFocus
Why Rhythm Pharmaceuticals Stock is Climbing High - TipRanks
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Yahoo
Rhythm Pharmaceuticals’ Unexpected Surge: A Stock to Watch? - timothysykes.com
Rhythm Pharma's drug for rare obesity meets late-stage trial goal - MSN
Rhythm Pharmaceuticals (RYTM) Reports Promising Phase 3 Trial Re - GuruFocus
Rhythm Pharmaceuticals (RYTM) Achieves Phase 3 Trial Success wit - GuruFocus
Rhythm Pharmaceuticals stock rises on trial success By Investing.com - Investing.com India
Rhythm Pharmaceuticals stock rises on trial success - Investing.com Australia
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in trial - MSN
Rhythm Pharmaceuticals' Obesity Treatment Meets Main Goal in Phase 3 Study, Shares Rise - MarketScreener
Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity - MarketScreener
Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results - TipRanks
Rhythm Pharmaceuticals says Phase 3 TRANSCEND trial meets primary endpoint - TipRanks
Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide - Nasdaq
Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial - MarketScreener
Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewswire
Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint with -19.8% - MarketScreener
Vanguard Group Inc. Trims Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
2.51%
자본화:
|
볼륨(24시간):